Fulcrum Therapeutics (FULC) Total Liabilities (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Total Liabilities data on file, last reported at $13.5 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 4.91% year-over-year to $13.5 million in Q1 2026; TTM through Mar 2026 was $13.5 million, a 4.91% decrease from a year earlier, with the FY2025 full-year figure at $17.3 million, down 2.26% from the prior year.
• Total Liabilities for Q1 2026 stood at $13.5 million, down from $17.3 million in the prior quarter.
• Over the last five years, Total Liabilities for FULC reached as high as $34.5 million in Q2 2022 and fell as low as $13.5 million in Q1 2026.
• Historically, Total Liabilities has averaged $21.8 million across 5 years, with a median of $21.7 million in 2024.
• Across the five-year window, Total Liabilities advanced 27.75% in 2022 and slipped 29.35% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $27.7 million in 2022, then slipped by 18.89% to $22.5 million in 2023, then slipped by 21.41% to $17.7 million in 2024, then retreated by 2.26% to $17.3 million in 2025, then fell by 22.08% to $13.5 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $13.5 million in Q1 2026, $17.3 million in Q4 2025, and $16.5 million in Q3 2025.